Cohen JA - Search Results

1

Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.

Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Vollmer TL, et al. Among authors: cohen ja. Mult Scler Relat Disord. 2020 Nov;46:102454. doi: 10.1016/j.msard.2020.102454. Epub 2020 Aug 18. Mult Scler Relat Disord. 2020. PMID: 33045496 Free article. Clinical Trial.

2

Management of multiple sclerosis.

Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Rudick RA, et al. Among authors: cohen ja. N Engl J Med. 1997 Nov 27;337(22):1604-11. doi: 10.1056/NEJM199711273372207. N Engl J Med. 1997. PMID: 9371858 Review. No abstract available.

3

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: cohen ja. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.

4

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders.

Cohen JA, Carter JL, Kinkel RP, Schwid SR. Cohen JA, et al. J Neuroimmunol. 1999 Jul 1;98(1):29-36. doi: 10.1016/s0165-5728(99)00078-8. J Neuroimmunol. 1999. PMID: 10426359 Review.

5

Multiple sclerosis: the importance of early recognition and treatment.

Fox RJ, Cohen JA. Fox RJ, et al. Among authors: cohen ja. Cleve Clin J Med. 2001 Feb;68(2):157-71. doi: 10.3949/ccjm.68.2.157. Cleve Clin J Med. 2001. PMID: 11220457 Free article.

6

Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis.

Marrie RA, Miller DM, Chelune GJ, Cohen JA. Marrie RA, et al. Among authors: cohen ja. Mult Scler. 2003 Dec;9(6):621-6. doi: 10.1191/1352458503ms971oa. Mult Scler. 2003. PMID: 14664477

7

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Fox RJ, et al. Among authors: cohen ja. Mult Scler. 2005 Apr;11(2):140-5. doi: 10.1191/1352458505ms1142oa. Mult Scler. 2005. PMID: 15794385 Clinical Trial.

8

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.

Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, Orav J, Stuart W, Weiner H. Smith DR, et al. Among authors: cohen ja. Mult Scler. 2005 Oct;11(5):573-82. doi: 10.1191/1352458505ms1210oa. Mult Scler. 2005. PMID: 16193896 Clinical Trial.

9

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Goodman AD, et al. Among authors: cohen ja, cohen r. Mult Scler. 2007 Apr;13(3):357-68. doi: 10.1177/1352458506069538. Epub 2007 Jan 29. Mult Scler. 2007. PMID: 17439905 Clinical Trial.

10

Emerging therapies for relapsing multiple sclerosis.

Cohen JA. Cohen JA. Arch Neurol. 2009 Jul;66(7):821-8. doi: 10.1001/archneurol.2009.104. Arch Neurol. 2009. PMID: 19597083 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

712 results

Search Page